Alder BioPharmaceuticals to Present at the 35th An
Post# of 301275
BOTHELL, Wash., Jan. 02, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 35th Annual J.P. Morgan Healthcare Conference at 4:00 p.m. PT (7:00 p.m. ET) on Monday, January 9, 2017 in San Francisco, CA. The presentation will feature a corporate overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com , or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for 30 days after the live event concludes.
Link: http://jpmorgan.metameetings.com/confbook/hea...nk?p=22492
About Alder BioPharmaceuticals, Inc. Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com .
Media Contacts: David Schull or Todd Davenport, Ph.D. Russo Partners, LLC (212) 845-4271 (212) 845-4235 Investor Relations Contact: David Walsey Alder BioPharmaceuticals (425) 408-8032
(0)
(0)